Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: A randomized, active-controlled, multi-center study Academic Article uri icon

Overview

MeSH Major

  • Anemia, Iron-Deficiency
  • Ferric Compounds
  • Iron
  • Maltose
  • Renal Dialysis
  • Renal Insufficiency, Chronic

abstract

  • FCM in doses of 200 mg for HD-CKD patients and up to 1000 mg in NDD-CKD patients were well tolerated and displayed comparable efficacy to other IV iron formulations.

publication date

  • April 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/ndt/gfs528

PubMed ID

  • 23222534

Additional Document Info

start page

  • 953

end page

  • 64

volume

  • 28

number

  • 4